A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 457
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : NAbs
Long Form : neutralizing antibodies
No. Year Title Co-occurring Abbreviation
2019 A cross-reactive human monoclonal antibody targets the conserved H7 antigenic site A from fifth wave H7N9-infected humans. HA, HI
2019 A single-arm, open-label study to assess the immunogenicity, safety, and efficacy of etanercept manufactured using the serum-free, high-capacity manufacturing process administered to patients with rheumatoid arthritis. ACR, ADAs, AEs, ETN, RA, SFHCM
2019 A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey. sE2
2019 Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies. AAV
2019 Adeno-associated virus neutralising antibodies in type 1 diabetes mellitus. AAVs
2019 Assessing cross-reactivity of Junin virus-directed neutralizing antibodies. BSL, GP, JUNV, trVLP
2019 Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies. ADAs, mAbs, PCSK9
2019 Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. ADA, TE-POS
2019 Associations of pathogen-specific and host-specific characteristics with disease outcome in patients with Staphylococcus aureus bacteremic pneumonia. AT, SA
10  2019 Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines. NIH
11  2019 Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. ---
12  2019 Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive In Vitro Assays. AAV8
13  2019 Development of Whole-Porcine Monoclonal Antibodies with Potent Neutralization Activity against Classical Swine Fever Virus from Single B Cells. CSF, CSFV
14  2019 Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. BENEFIT, BEYOND, MS, OR, SNPs
15  2019 Effects of Neutralizing Antibody Production on AAV-PHP.B-Mediated Transduction of the Mouse Central Nervous System. AAV, CSF
16  2019 Efficacy and Safety of Asfotase Alfa in Infants and Young Children With Hypophosphatasia: A Phase 2 Open-Label Study. HPP, RGI-C
17  2019 Evaluation of a Rapid Immunochromatographic Assay and Two Enzyme-Linked Immunosorbent Assays for Detection of IgM-Class Antibodies to Zika Virus. DENV, ICA, PRNT, WNV, ZIKV
18  2019 Evolution of the Envelope Glycoprotein of HIV-1 Clade B toward Higher Infectious Properties over the Course of the Epidemic. Env
19  2019 Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy. BCMNs, OA
20  2019 HCMV trimer- and pentamer-specific antibodies synergize for virus neutralization but do not correlate with congenital transmission. HCMV
21  2019 Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms. HCV, HVR1
22  2019 High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. ---
23  2019 Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations. HCV, HVR1
24  2019 Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes. CDRs, EBV, gp350, m72A1, mAb
25  2019 Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates. AAV, hFIX, hSEAP, IA, rAAV5
26  2019 Immunogenicity induced by botulinum toxin injections for limb spasticity: A systematic review. BoNT, SnR
27  2019 Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs. ADAs, AEs, RA
28  2019 Induction of neutralizing antibodies against tier 2 human immunodeficiency virus 1 in rhesus macaques infected with tier 1B simian/human immunodeficiency virus. MK1, MK38, SHIV, wpi
29  2019 Intravenous Immunoglobulin Administration Significantly Increases BKPyV Genotype-Specific Neutralizing Antibody Titers in Kidney Transplant Recipients. BKPyV, IVIG, KTR
30  2019 Perinatal analyses of Zika- and dengue virus-specific neutralizing antibodies: A microcephaly case-control study in an area of high dengue endemicity in Brazil. DENV, PCA, ZIKV
31  2019 Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance. bNAb, HCV
32  2019 Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies. bNAbs, Env
33  2019 Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients. AAV, DMD
34  2019 Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome. AAV, AAV8, CN
35  2019 Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors. AAV, IFN-gamma, IL-2
36  2019 Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus. bNAbs, CAP256 SU, Env, MVA, VLPs
37  2019 Rapid AAV-Neutralizing Antibody Determination with a Cell-Binding Assay. rAAV
38  2019 Relationship Between Neutralizing Antibodies Against Adeno-Associated Virus in the Vitreous and Serum: Effects on Retinal Gene Therapy. AAV, BRB, VH
39  2019 Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study. CI, GMTs, RSV
40  2019 Sero-molecular epidemiology of enterovirus-associated encephalitis in Zhejiang Province, China, from 2014 to 2017. ---
41  2019 Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. vp
42  2019 Superior human hepatocyte transduction with adeno-associated virus vector serotype 7. AAV
43  2019 Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs. AAV, hFIX, NHPs
44  2019 Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. SHIV
45  2019 Viral Characteristics Associated with Maintenance of Elite Neutralizing Activity in Chronically HIV-1 Clade C-Infected Monozygotic Pediatric Twins. bnAbs, CD4bs
46  2018 A tetravalent vaccine comprising hexon-chimeric adenoviruses elicits balanced protective immunity against human adenovirus types 3, 7, 14 and 55. Ad
47  2018 Alemtuzumab depletion failure can occur in multiple sclerosis. ---
48  2018 Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-alpha. BAbs, CR, MPNs
49  2018 Antibody Responses to a Quadrivalent Hepatitis C Viral-Like Particle Vaccine Adjuvanted with Toll-Like Receptor 2 Agonists. HCV, TLR2, VLP
50  2018 Carrier Cells for Delivery of Oncolytic Measles Virus into Tumors: Determinants of Efficient Loading. OMV
51  2018 Creating an arsenal of Adeno-associated virus (AAV) gene delivery stealth vehicles. AAV, cryo-EM
52  2018 Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay. ADA, CI-M6PR, ERTs
53  2018 Dissection of Epitope-Specific Mechanisms of Neutralization of Influenza Virus by Intact IgG and Fab Fragments. Ab, EM, HA, NAb
54  2018 Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. ---
55  2018 Human Parechovirus 1, 3 and 4 Neutralizing Antibodies in Dutch Mothers and Infants and Their Role in Protection Against Disease. HPeVs
56  2018 Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry. HCV, HVR1, SR-BI
57  2018 Identification of a novel broadly HIV-1-neutralizing antibody from a CRF01_AE-infected Chinese donor. CDR, SHMs
58  2018 Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors. Ad, ChAd, HuAd, RhAd
59  2018 Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120. mAbs
60  2018 Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction. AAV, BAbs
61  2018 Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta. CPE, MS, pegIFNbeta-1a, rIFNbeta
62  2018 Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans. AAVs
63  2018 Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis. IFN-beta, MS
64  2018 Optimization of the EC26-2A4 Epitope in the gp41 Membrane Proximal External Region Targeted by Neutralizing Antibodies from an Elite Controller. Env, LTNP, mAb
65  2018 Screening for Neutralizing Antibodies Against Natural and Engineered AAV Capsids in Nonhuman Primate Retinas. AAV, NHPs
66  2018 Seroepidemiological investigation of HAdV-4 infection among healthy adults in China and in Sierra Leone, West Africa. HAdV-4
67  2018 Serological survey of neutralizing antibodies to eight major enteroviruses among healthy population. CV-A6, CV-B3, CVA10, CVA16, CVB5, ECHO25, ECHO30, EV-A71, EVs, HA, HFMD
68  2018 Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients. ---
69  2018 Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. Env
70  2018 Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies. bNAbs, Env
71  2018 Structure-Based Design of Porcine Circovirus Type 2 Chimeric VLPs (cVLPs) Displays Foreign Peptides on the Capsid Surface. Cap, cVLPs, MP-Lcd, VLPs
72  2018 The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein. AR3, AS412, AS434, CD81bl, FL, HCV
73  2018 Utilization of Feline ELISpot to Evaluate the Immunogenicity of a T Cell-Based FIV MAP Vaccine. Env, FIV, IFN-gamma, IL-2, MAPs, PBMC
74  2018 V4 region of the HIV-1 envelope gene mediates immune escape and may not promote the development of broadly neutralizing antibodies. bNAbs, p.i, ss-Abs, T/F
75  2018 When designing vaccines, consider the starting material: the human B cell repertoire. ---
76  2017 An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab. ADA, MM, SLAMF7
77  2017 Antibody-dependent NK cell degranulation as a marker for assessing antibody-dependent cytotoxicity against pandemic 2009 influenza A(H1N1) infection in human plasma and influenza-vaccinated transchromosomic bovine intravenous immunoglobulin therapy. ADCC
78  2017 BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV. KSHV, UV-KSHV, VLPs
79  2017 Broadly Neutralizing Antibody Responses in a Subset of HIV-1-Infected Individuals in Chennai, India. ---
80  2017 Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway. IFN-beta, MS
81  2017 Dengue Virus Evades AAV-Mediated Neutralizing Antibody Prophylaxis in Rhesus Monkeys. ADE, DENV3, IgG, rAAVs, rhIgG1
82  2017 Development of a novel Newcastle disease virus (NDV) neutralization test based on recombinant NDV expressing enhanced green fluorescent protein. EGFP, eGFP-NT, HI, NDV, NT
83  2017 Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution. ART, HIV-1
84  2017 Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction. CD4bs
85  2017 Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors. ADAs, PD-1
86  2017 Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents. ADAs, ECL, RP
87  2017 Germinal Center Lymphocyte Ratios and Successful HIV Vaccines. Env, Tfh
88  2017 Immunization With a Subunit Hepatitis C Virus Vaccine Elicits Pan-Genotypic Neutralizing Antibodies and Intrahepatic T-Cell Responses in Nonhuman Primates. DAAs, HCV, HCV, sE2
89  2017 Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. bNAbs, Env, HIV-1
90  2017 In vitro inhibition of HIV-1 replication in autologous CD4+ T cells indicates viral containment by multifactorial mechanisms. CTLs, NKs
91  2017 Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity. HEU, MTCT
92  2017 Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNbeta. MxA
93  2017 Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines. Ad2, HIV
94  2017 Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir. CpG, FI-HSV2, HSV-2, MPL, TLR
95  2017 Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. bNAbs, HIV-1, non-NAbs, sCD4
96  2017 Secreted Expression of the Cap Gene of Porcine Circovirus Type 2 in Classical Swine Fever Virus C-Strain: Potential of C-Strain Used as a Vaccine Vector. Cap, CSFV, NLS, PCV2
97  2017 Seroepidemiology of enterovirus D68 infection in China. ---
98  2017 Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China. Ad14, MN
99  2017 Strain-dependent neutralization reveals antigenic variation of human parechovirus 3. HPeV3, IVIG, mAb
100  2017 Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. AAVs